Literature DB >> 4208278

Biliary excretion of a new semisynthetic cephalosporin, cephacetrile.

J M Brogard, P Haegele, M Dorner, J Lavillaureix.   

Abstract

The biliary excretion of a new derivative of cephalosporin, cephacetrile (CIBA 36 278 Ba), was studied (i) in the isolated perfused rabbit liver, (ii) in humans with a duodenal tube, and (iii) in patients after cholecystectomy with a Kehr's drain in the common bile duct. The biliary excretion of the antibiotic was very low in the perfused liver, and no antibiotic activity was found in liver tissue at the end of the experiment. This observation, together with the finding of a rapid decline of the antibiotic concentration in the circulating blood serum, favors the assumption that a metabolic transformation of CIBA 36 278 Ba in liver tissue takes place. In humans, the antibiotic concentration was found to be low both in the duodenal juice and in the bile obtained by external drainage. The biliary concentrations found in these subjects seem to be inferior to those required for the inhibition of the common bacteria of biliary infections. In renal failure, however, the biliary excretion of CIBA 36 278 Ba increased considerably.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4208278      PMCID: PMC444354          DOI: 10.1128/AAC.3.1.19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  CIBA 36278-Ba" chemotherapy and toxicology in laboratory animals.

Authors:  F Kradolfer; W Sackmann; O Zak; H Brunner; R Hess; E A Konopka; J Gelzer
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

2.  Antimicrobial studies in vitro with CIBA 36278-Ba, a new cephalosporin derivative.

Authors:  F Knüsel; E A Konopka; J Gelzer; A Rosselet
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

3.  [Experimental study and human pharmacology of the biliary excretion of a cephalosporin, cephalexin. Therapeutical application].

Authors:  J M Brogard; F Kuntzmann; M Dorner; P Haegele; J Lavillaureix
Journal:  Pathol Biol (Paris)       Date:  1971-12
  3 in total
  9 in total

Review 1.  Drug monitoring in nonconventional biological fluids and matrices.

Authors:  S Pichini; I Altieri; P Zuccaro; R Pacifici
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

2.  Multicentre comparison of cephacetrile and ampicillin in the treatment of urinary tract infections.

Authors:  C Ponticelli; P Zucchelli; G Casucci; I Cervellati; C Dalla Rosa; C Giro; M Motolese
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

Review 3.  Newer beta-lactam antibiotics.

Authors:  J M Hamilton-Miller; W Brumfitt
Journal:  Infection       Date:  1974       Impact factor: 3.553

4.  Biliary excretion of aztreonam in patients with biliary tract disease.

Authors:  O V Martinez; J U Levi; R G Devlin
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Laboratory evaluation of FR10024 a new cephalosporin derivative.

Authors:  M Nishida; T Murakawa; T Kamimura; N Okada; S Fukada
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

6.  Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

Authors:  K R Ratzan; C Ruiz; G L Irvin
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

Review 7.  Biliary excretion of drugs in man.

Authors:  D E Rollins; C D Klaassen
Journal:  Clin Pharmacokinet       Date:  1979 Sep-Oct       Impact factor: 6.447

8.  Double-blind comparison of cephacetrile with cephalothin-cephaloridine.

Authors:  G G Jackson; L J Riff; V M Zimelis; M Daood; M Youssuf
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

9.  Influence of renal function on the pharmacokinetics of diacerein after a single oral dose.

Authors:  P Debord; K Louchahi; M Tod; A Cournot; G Perret; O Petitjean
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.